Dendreon Corporation DNDN today announced the sale of its
immunotherapy manufacturing facility (IMF) based in Morris Plains, New Jersey,
to Novartis Pharmaceuticals Corporation NVS for $43 million in cash.
Dendreon's Morris Plains, New Jersey, facility is a 173,100 square foot
state-of-the-art IMF, featuring revolutionary capabilities to manufacture
PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy to
receive U.S. Food and Drug Administration approval for the treatment of
asymptomatic or minimally symptomatic metastatic castrate resistant prostate
cancer. Earlier this year, Dendreon announced its intent to wind down the
manufacturing of PROVENGE® at the Morris Plains facility in conjunction with a
strategic restructuring plan designed to accelerate the Company's path to
profitability and future growth.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsAsset Sales
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in